Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

Biotechnology • Healthcare • Menlo Park, CA, United States • ORKA (NGM)

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3% - Should You Buy? - MarketBeat
MarketBeat • Dec 31
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka Therapeutics Inc (ORKA) - GuruFocus
GuruFocus • Jan 3
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com
Investing.com • Dec 22
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
GlobeNewswire • Nov 12
Oruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M Offering - Yahoo Finance
Yahoo Finance • Oct 10

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Oruka Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Oruka Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Oruka Therapeutics, Inc. have?
Oruka Therapeutics, Inc. has approximately 28 employees.
What industry is Oruka Therapeutics, Inc. in?
Oruka Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Oruka Therapeutics, Inc. a publicly traded company?
Yes, Oruka Therapeutics, Inc. is publicly traded under the ticker symbol ORKA on the NGM. The company has a market capitalization of approximately $1.55 billion.
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc. is headquartered in Menlo Park, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.